All News

Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.

Your daily dose of the clinical news you may have missed.

Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.

The risk of a suicide attempt was 2 times greater among those with headache, across types including tension type headache, migraine, trigeminal autonomic cephalalgia, and posttraumatic headache.

Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.

The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.

Post-traumatic headaches and trigeminal autonomic cephalalgia significantly increased the risk for attempted and completed suicide, according to new study.

An anesthesiologist and renowned investigator in use of nonopioids as part of multimodal pain management, Edward Mariano, MD, MAS, describes slow uptake in the field.

AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.

Your daily dose of the clinical news you may have missed.